Just five days after raising $105 million in a series E financing round, RNA interference therapeutics specialist Sirnaomics Inc. obtained another IND approval from the FDA for its dual-targeting small interfering RNA (siRNA) inhibitor STP-707 to start a basket study in oncology. Sirnaomics’ CEO Patrick Lu told BioWorld in an exclusive interview that an I.V. administration of STP-707 will be tested to tackle solid cancers that may have metastasized into other potential areas or tissue types in the body.

DUBLIN – Investment in European biotechnology slowed dramatically during the second quarter, as the funding frenzy of the first three months of the year gave way to a very solid but a less spectacular performance. Collectively, European firms engaged in drug discovery and development raised $3.358 billion in disclosed transactions during the second quarter, down 46% from the $6.195 billion raised during the first quarter.

Looking to allow customers to directly purchase its diagnostics system that runs a full panel of blood tests, Babson Diagnostics Inc. raised $31 million in new series B financing. The proceeds will be used to scale the Austin, Texas-based company to bring its finger-prick blood microsampling system to retail locations across the country.

It’s a good time to be a virtual research organization, with investors apparently eager to get into the segment. As part of that trend, Obviohealth Inc. reported it raised $31 million in series B financing, following on the heels of 4G Clinical's announcement on Tuesday of a $230 million investment by Goldman Sachs Asset Management and a $280 million transaction for Science 37 in May 2021.